<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cynata Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd</link>
<description>Latest news and press releases for Cynata Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 02:19:04 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cynata-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683664a078dffbe2df15d3ae.webp</url>
<title>Cynata Therapeutics Ltd</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd</link>
</image>
<item>
<title>Last Visit in GvHD Trial Completed</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/last-visit-in-gvhd-trial-completed</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/last-visit-in-gvhd-trial-completed</guid>
<pubDate>Mon, 30 Mar 2026 02:19:04 GMT</pubDate>
<description>Last Visit in GvHD Trial Completed</description>
</item>
<item>
<title>Appendix 4D & Half-Year Financial Statements</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/appendix-4d-and-half-year-financial-statements-18</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/appendix-4d-and-half-year-financial-statements-18</guid>
<pubDate>Thu, 26 Feb 2026 10:04:10 GMT</pubDate>
<description>Appendix 4D & Half-Year Financial Statements</description>
</item>
<item>
<title>December 2025 Quarterly Activity Report and Appendix 4C</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/december-2025-quarterly-activity-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/december-2025-quarterly-activity-report-and-appendix-4c-2</guid>
<pubDate>Thu, 29 Jan 2026 03:51:08 GMT</pubDate>
<description>December 2025 Quarterly Activity Report and Appendix 4C</description>
</item>
<item>
<title>Cynata Completes $1.2m At-The-Market Raise</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/cynata-completes-dollar12m-at-the-market-raise</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/cynata-completes-dollar12m-at-the-market-raise</guid>
<pubDate>Fri, 23 Jan 2026 12:02:04 GMT</pubDate>
<description>Cynata Completes $1.2m At-The-Market Raise</description>
</item>
<item>
<title>Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/patient-enrolment-complete-in-phase-2-agvhd-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/patient-enrolment-complete-in-phase-2-agvhd-clinical-trial</guid>
<pubDate>Mon, 15 Dec 2025 03:30:11 GMT</pubDate>
<description>Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial</description>
</item>
<item>
<title>Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/patient-enrolment-completed-phase-2-002500068</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/patient-enrolment-completed-phase-2-002500068</guid>
<pubDate>Mon, 15 Dec 2025 00:25:00 GMT</pubDate>
<description>Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001 in adults with newly diagnosed, high risk acute graft versus host disease (aGvHD).</description>
</item>
<item>
<title>Positive DSMB Review in Phase 1/2 Kidney Transplant Trial</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/positive-dsmb-review-in-phase-12-kidney-transplant-trial</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/positive-dsmb-review-in-phase-12-kidney-transplant-trial</guid>
<pubDate>Thu, 04 Dec 2025 03:16:05 GMT</pubDate>
<description>Positive DSMB Review in Phase 1/2 Kidney Transplant Trial</description>
</item>
<item>
<title>Final Patient Visit Complete in Phase 3 Osteoarthritis Trial</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/final-patient-visit-complete-in-phase-3-osteoarthritis-trial</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/final-patient-visit-complete-in-phase-3-osteoarthritis-trial</guid>
<pubDate>Mon, 24 Nov 2025 03:45:15 GMT</pubDate>
<description>Final Patient Visit Complete in Phase 3 Osteoarthritis Trial</description>
</item>
<item>
<title>Cynata Receives $1.7m R&D Tax Incentive Refund</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/cynata-receives-dollar17m-randd-tax-incentive-refund</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/cynata-receives-dollar17m-randd-tax-incentive-refund</guid>
<pubDate>Wed, 05 Nov 2025 06:34:08 GMT</pubDate>
<description>Cynata Receives $1.7m R&D Tax Incentive Refund</description>
</item>
<item>
<title>September 2025 Quarterly Activity Report and Appendix 4C</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/september-2025-quarterly-activity-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/september-2025-quarterly-activity-report-and-appendix-4c-2</guid>
<pubDate>Fri, 31 Oct 2025 06:57:04 GMT</pubDate>
<description>September 2025 Quarterly Activity Report and Appendix 4C</description>
</item>
<item>
<title>Appendix 4E & Annual Report</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/appendix-4e-and-annual-report-86</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/appendix-4e-and-annual-report-86</guid>
<pubDate>Thu, 28 Aug 2025 12:43:18 GMT</pubDate>
<description>Appendix 4E & Annual Report</description>
</item>
<item>
<title>At-the-Market Subscription Agreement</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/at-the-market-subscription-agreement-1</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/at-the-market-subscription-agreement-1</guid>
<pubDate>Fri, 22 Aug 2025 03:17:59 GMT</pubDate>
<description>At-the-Market Subscription Agreement</description>
</item>
<item>
<title>June 2025 Quarterly Activity Report and Appendix 4C</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/june-2025-quarterly-activity-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/june-2025-quarterly-activity-report-and-appendix-4c-2</guid>
<pubDate>Wed, 30 Jul 2025 04:06:12 GMT</pubDate>
<description>June 2025 Quarterly Activity Report and Appendix 4C</description>
</item>
<item>
<title>CYP-001s FDA Approval Pathway Not Impeded</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/cyp-001s-fda-approval-pathway-not-impeded</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/cyp-001s-fda-approval-pathway-not-impeded</guid>
<pubDate>Fri, 16 May 2025 06:33:11 GMT</pubDate>
<description>CYP-001s FDA Approval Pathway Not Impeded</description>
</item>
<item>
<title>March 2025 Quarterly Activity Report and Appendix 4C</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/march-2025-quarterly-activity-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/march-2025-quarterly-activity-report-and-appendix-4c-2</guid>
<pubDate>Thu, 24 Apr 2025 07:32:11 GMT</pubDate>
<description>March 2025 Quarterly Activity Report and Appendix 4C</description>
</item>
<item>
<title>Publication comparing Cymerus MSCs to other MSCs</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/publication-comparing-cymerus-mscs-to-other-mscs</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/publication-comparing-cymerus-mscs-to-other-mscs</guid>
<pubDate>Wed, 05 Feb 2025 03:33:14 GMT</pubDate>
<description>Publication comparing Cymerus MSCs to other MSCs</description>
</item>
<item>
<title>Quarterly Activity Report & Appendix 4C</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/quarterly-activity-report-and-appendix-4c-17</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/quarterly-activity-report-and-appendix-4c-17</guid>
<pubDate>Thu, 30 Jan 2025 03:12:20 GMT</pubDate>
<description>Quarterly Activity Report & Appendix 4C</description>
</item>
<item>
<title>First Kidney Transplant Trial Patient Treated</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/first-kidney-transplant-trial-patient-treated</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/first-kidney-transplant-trial-patient-treated</guid>
<pubDate>Thu, 12 Dec 2024 03:12:16 GMT</pubDate>
<description>First Kidney Transplant Trial Patient Treated</description>
</item>
<item>
<title>Cynata secures commitments for $8.1m institutional placement</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/cynata-secures-commitments-for-dollar81m-institutional-placement</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/cynata-secures-commitments-for-dollar81m-institutional-placement</guid>
<pubDate>Fri, 06 Dec 2024 03:57:14 GMT</pubDate>
<description>Cynata secures commitments for $8.1m institutional placement</description>
</item>
<item>
<title>Demonstrated Safety & Efficacy in DFU Clinical Trial</title>
<link>https://6ix.com/company/cynata-therapeutics-ltd/news/demonstrated-safety-and-efficacy-in-dfu-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/cynata-therapeutics-ltd/news/demonstrated-safety-and-efficacy-in-dfu-clinical-trial</guid>
<pubDate>Thu, 05 Dec 2024 05:00:14 GMT</pubDate>
<description>Demonstrated Safety & Efficacy in DFU Clinical Trial</description>
</item>
</channel>
</rss>